Your browser doesn't support javascript.
loading
Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor.
Kaino, Akira; Niizuma, Hidetaka; Katayama, Saori; Irie, Masahiro; Nakano, Tomohiro; Sato, Daichi; Saito, Tsuyoshi; Kato, Shunsuke; Suehara, Yoshiyuki; Sasahara, Yoji; Kikuchi, Atsuo.
Afiliação
  • Kaino A; Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
  • Niizuma H; Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
  • Katayama S; Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
  • Irie M; Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
  • Nakano T; Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
  • Sato D; Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
  • Saito T; Department of Human Pathology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan.
  • Kato S; Department of Medical Oncology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan.
  • Suehara Y; Department of Medicine for Orthopaedics and Motor Organ, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan.
  • Sasahara Y; Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
  • Kikuchi A; Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
Pediatr Blood Cancer ; 70(8): e30330, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37017194

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article